Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Ford

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Annals of the American Thoracic Society|March 3, 2022
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association RegistryRoberto J Bernardo, Di Lu, Ramon L Ramirez, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providersKaren H Lu, Marie E Wood, Molly Daniels, et al.
Health Policy and Planning|November 23, 2023
Justice implications of health and food security policies for Indigenous peoples facing COVID-19: a qualitative study and policy analysis in PeruVictoria Chicmana-Zapata, Ingrid Arotoma-Rojas, Cecilia Anza-Ramírez, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 23, 2017
Long-read genome sequencing identifies causal structural variation in a Mendelian diseaseJason D Merker, Aaron M Wenger, Tam Sneddon, et al.
Journal of Psychosocial Oncology|November 20, 2025
Assessing delivery of and attitudes toward a randomized intervention to increase mammography uptake among childhood cancer survivors: A report from the Childhood Cancer Survivor StudyHan-Wei V Wu, Kevin C Oeffinger, Joanne F Chou, et al.
The European Respiratory Journal|November 27, 2020
EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHARMarissa Borgese, David Badesch, Todd Bull, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor StudyKevin C Oeffinger, Jennifer S Ford, Chaya S Moskowitz, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Annals of the American Thoracic Society|March 3, 2022
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association RegistryRoberto J Bernardo, Di Lu, Ramon L Ramirez, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providersKaren H Lu, Marie E Wood, Molly Daniels, et al.
Health Policy and Planning|November 23, 2023
Justice implications of health and food security policies for Indigenous peoples facing COVID-19: a qualitative study and policy analysis in PeruVictoria Chicmana-Zapata, Ingrid Arotoma-Rojas, Cecilia Anza-Ramírez, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 23, 2017
Long-read genome sequencing identifies causal structural variation in a Mendelian diseaseJason D Merker, Aaron M Wenger, Tam Sneddon, et al.
Journal of Psychosocial Oncology|November 20, 2025
Assessing delivery of and attitudes toward a randomized intervention to increase mammography uptake among childhood cancer survivors: A report from the Childhood Cancer Survivor StudyHan-Wei V Wu, Kevin C Oeffinger, Joanne F Chou, et al.
The European Respiratory Journal|November 27, 2020
EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHARMarissa Borgese, David Badesch, Todd Bull, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor StudyKevin C Oeffinger, Jennifer S Ford, Chaya S Moskowitz, et al.
Pageof 12